OWC Pharmaceutical Research Corp. is engaged in the business, through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., of conducting medical research and clinical trials, in full compliance with all international regulatory protocols, for the development of cannabis-based products and treatments specifically designed for multiple myeloma, psoriasis, fibromyalgia, PTSD, migraines, and of a unique delivery system.
OWC Pharmaceutical Research corp. was incorporated in Delaware on March 7, 2008, under the name Dynamic Applications Corp. On November 25, 2014 the Company’s Board of Directors approved an amendment to the Company’s Certificate of Incorporation to affect the name change with the written consent of the Company’s majority consenting stockholders.
OWC Pharmaceutical Research is traded in the OTCQB market with the symbol OWCP.
For further information see the Company’s SEC filing in INVESTORS.
One World Cannabis Ltd., a wholly owned Israeli subsidiary of OWC Pharmaceutical Research Corp. (OTCQB:OWCP), is focused on discovering, developing and commercializing cannabis-based novel therapeutics products and treatments specifically designed for several medical conditions, starting with multiple myeloma, psoriasis, fibromyalgia, PTSD (post-traumatic stress disorder) and migraines.
One World Cannabis is a young company that, despite its youth, is already playing a part in making history.
The expert team delivers years of proven practices in diverse disciplines, including medical science and regulatory affairs, as well as extensive cannabis-related issues experience.
One World Cannabis aspires to become one of the world’s leading players in the hyper-growing market of medical cannabis by providing the missing yet prerequisite element of scientific validity for cannabis based products.
The Company is committed to and the highest standards of integrity and ethics in proposing, conducting and reporting research. All its investigations and researches are conducted at the facilities of leading Israeli medical centers, as well as at the labs of the R&D pharmaceutical companies we contracted with. The Company adheres to all the necessary regulatory requirements, including submitting its research protocols to Ethics Committee (IRB) approval.
When it comes to medical cannabis, OWC believes in science instead of mythology.
We aim to produce pharmaceutical-grade cannabis-based products and treatments that are:-
- Standardized in composition, formulation and dose;
- Administered by means of the appropriate and efficient innovative delivery systems; and –
- Tested in properly controlled pre-clinical and clinical studies.
We believe that its planned products will provide physicians with the ability to control and administrate optimal dosage, and to replace the common usage of medical cannabis today, which is not acceptable by scientists and physicians, such as smoking, edibles and oil extracts with no substantial dosage control.
We also believe that our planned products will provide patients with the absolute assurance that they are purchasing and taking products that are clinically tested, safe, efficient and consistent.